Sanofi SA :Sanofi Initiates Phase 3 Program For Pcv21 And Expands Collaboration With Sk Bioscience For Next-Generation Pneumococcal Conjugate Vaccines.Pcv21 First Vaccine With 20+ Serotypes To Enter Phase 3.To Commercialize Vaccines Worldwide Except South Korea.To Pay Eur 50M Upfront To Sk Bioscience.